HOOKIPA Pharma (HOOK) Q3 2024 earnings summary

Executive summary

• HOOKIPA is a clinical-stage biopharma focused on arenavirus-based immunotherapeutics, with lead programs in oncology and infectious diseases, including eseba-vec for HPV16+ head and neck cancers and partnered HBV/HIV programs with Gilead.

• Completed enrollment of 68 patients in Phase 2 eseba-vec + pembrolizumab study for HPV+ HNSCC four months ahead of schedule.

• Presented updated Phase 2 data at SITC 2024 showing durable clinical and antigen-specific T cell responses.

• Advanced HB-700 KRAS-inhibitor program with strong preclinical data and FDA IND clearance.

• The company reprioritized its pipeline in 2024, pausing HB-300 and most preclinical work, and implemented two workforce reductions totaling about 50% of staff.

Financial highlights

• Revenue for Q3 2024 was $4.7M, down from $6.9M in Q3 2023; nine-month revenue rose to $42.6M from $12.7M year-over-year, mainly due to accelerated recognition from the Roche agreement termination.

• Net loss for Q3 2024 was $13.8M, improved from $19.1M in Q3 2023; nine-month net loss was $18.6M, a significant improvement from $56.8M in the prior year period.

• Research and development expenses decreased to $15.6M in Q3 2024 from $24.6M in Q3 2023, and to $55.5M for the nine months from $65.3M year-over-year.

• Cash, cash equivalents, and restricted cash totaled $60.0M as of September 30, 2024, down from $117.5M at year-end 2023.

• Received a $5M milestone payment from Gilead for HB-500 clinical progress.

Outlook and guidance

• Management expects continued operating losses and negative cash flows, with substantial doubt about the company’s ability to continue as a going concern for at least 12 months without additional funding.

• Plans to seek further capital through equity, debt, grants, or partnerships; failure to secure funding may require further cost reductions or program delays.

• Ongoing review and optimization of business strategy and operations to prioritize resources and spending.

• Forward-looking statements highlight substantial risks and uncertainties in drug development, regulatory processes, and funding sufficiency.